Clinical Trials Logo

Clinical Trial Summary

Women in the menopause transition ('perimenopause') are exposed to extreme hormone variability, tend to experience a unique set of severe stressors (e.g., divorce, death of loved ones), and are also at substantially elevated risk to suffer from mood and anxiety disorders. The purpose of this research is to understand the mechanisms by which variability in estradiol (E2) is associated with the symptoms of anxiety and anhedonia (loss of interest and pleasure - a common symptom of depression). By stabilizing E2 variability with a hormonal manipulation, this research will determine the degree to which the E2 variability (or E2 levels) plays a causal role in perimenopausal anxiety and anhedonia symptoms and whether it does so by affecting biological responses to stress.


Clinical Trial Description

Framed within a diathesis-stress model, the primary objective of this research is to determine the pathophysiological mechanisms of estradiol (E2) in the clinical anxiety and anhedonia seen in the menopause transition (MT). Specifically whether E2 variability or E2 levels predict exaggerated hypothalamic-pituitary-adrenal (HPA) axis reactivity and impaired recovery to stress and, in turn, deficits in behavioral indices of threat responsivity and approach motivation and symptoms of anxiety and anhedonia. The secondary objective of the research is to use a hormonal manipulation as a mechanistic probe to stabilize E2 variability in premenopausal ranges and determine if: a) HPA axis reactivity/recovery represents a biomarker of behavioral and symptom responses to E2 stabilization; b) whether recent severe life stress predicts the HPA axis response to hormone stabilization. A total of 170 women in the early or late MT who are eligible for the hormonal probe will be recruited to reflect the full continuum of anxiety and anhedonia symptoms based on self-report to the State-Trait Anxiety Inventory and the Snaith-Hamilton Pleasure Scale, respectively. However, the investigators will over-represent the clinically impairing end of the anxious and anhedonic phenotype (75% of the sample). Over an 8-week baseline, anxiety and anhedonia symptoms and serum E2 measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) will be assessed on a weekly basis. At baseline week 8, HPA axis (plasma cortisol and ACTH) response to the Trier Social Stress Test and behavioral measures of threat responsivity (via Dot-Probe task) and approach motivation (Effort Expenditure for Rewards Task 'EEfRT') will be determined. Using transdermal E2 as a pharmacological probe to stabilize variability of E2 in premenopausal ranges, women will then be randomized to transdermal E2 (0.10 mg) or placebo for 16 weeks. This is not a clinical efficacy trial. The investigators will use an randomized control trial (RCT) design with a hormonal manipulation in order to investigate the pathophysiologic role of E2 variability (or E2 levels) in HPA axis dysregulation and, in turn, threat responsivity and approach motivation. Serum E2 will be assessed weekly during weeks 9-16, and HPA axis reactivity to stress and behavioral responses to the Dot-Probe and EEfRT tasks will be assessed every four weeks during the 16 week probe. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03003949
Study type Interventional
Source University of North Carolina, Chapel Hill
Contact
Status Terminated
Phase Phase 4
Start date January 24, 2017
Completion date May 10, 2020

See also
  Status Clinical Trial Phase
Completed NCT04064151 - A Research Study for Latina Women Undergoing Breast Cancer Treatment N/A
Recruiting NCT04160611 - What Amount of Stress is Enough for a Successful Conception? Phase 3
Completed NCT02947477 - Emotion Tracking Study for Residents N/A
Recruiting NCT05083871 - Cognitive Appraisals and Team Performance Under Stress in Simulated Trauma Care
Active, not recruiting NCT05092542 - Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers N/A
Completed NCT03464955 - VR Usage in Non-Invasive Surgical Sub-Specialty Procedures N/A
Completed NCT06152549 - Online Emotional Response to Completing a Childhood Maltreatment Self-report Scale
Completed NCT04977726 - Resilience Curriculum for Novice Physicians-in-training N/A
Active, not recruiting NCT04545021 - My Health Day by Day (Mi Salud Dia a Dia)
Not yet recruiting NCT05799534 - Post-Coronavirus Disease of 2019 (COVID-19) Rehabilitation Clinics in Saudi Arabia N/A
Not yet recruiting NCT04173559 - Sleep and Tracking Effects in Pregnancy Study N/A
Completed NCT04927845 - StriveWeekly Trial Post-pandemic N/A
Active, not recruiting NCT04950816 - Examining the Feasibility and Acceptability of a Tailored Version of a Mindfulness-Based Intervention (MBI) Among Youth Experiencing Homelessness (YEH) Phase 1
Completed NCT03645005 - A Research Study for Latina Women After Breast Cancer Treatment N/A
Completed NCT04595084 - Remotely Delivered Programs Targeting COVID-19 Stress-Related Depression and Substance Use N/A
Enrolling by invitation NCT06085105 - Caring for Providers to Improve Patient Experience (CPIPE) Trial N/A
Completed NCT05933746 - Sleep Hygiene Intervention on Undergraduate Students' Sleep and Stress N/A
Enrolling by invitation NCT06063174 - Stress & Resilience Study N/A
Completed NCT05304000 - Psychophysiological Effects of Controlled Respiration and Mindfulness N/A
Completed NCT04441632 - Effect of Positive Attitudes on Behavior and Wellness N/A